Updated: 15 hours ago
In June 2026, China approved satricabtagene autoleucel (satri-cel), a CAR-T cell therapy for advanced stomach cancer — reported as the first CAR-T approved anywhere for a solid tumor (OncLive, June 2026). For patients whose stomach cancer has kept growing through two or more lines of treatment, that is a genuinely new option.
It is also a narrow one. Satri-cel works only for tumors that carry a protein called Claudin18.2, and its benefits, while real, are measured in months.
The short answer: China now offers an approved CAR-T for Claudin18.2-positive, HER2-negative advanced stomach and gastroesophageal junction (GEJ) cancer after at least two prior treatments, plus Chinese-developed immunotherapy and HER2-targeted drugs. Which applies to you depends on three biomarkers: Claudin18.2, HER2 and PD-L1.
Key Takeaways |
|
Table of Contents
Three Biomarkers That Decide Your Options
Most stomach cancers are adenocarcinomas. Before choosing drug treatment, doctors test the tumor for:
HER2 — about 1 in 5 stomach cancers; responds to HER2-targeted drugs.
PD-L1 (measured as CPS) — higher scores predict more benefit from immunotherapy.
Claudin18.2 — a protein on stomach cells; the target of satri-cel.
If your tumor hasn't been tested for Claudin18.2, ask for it. Many hospitals outside Asia don't test for it routinely, and without the result no one can tell you whether satri-cel applies.
Satri-cel: The First Approved CAR-T for Stomach Cancer
What it is. CAR-T therapy collects a patient's own T cells, engineers them in a lab to recognize a specific target — here, Claudin18.2 — and infuses them back. Satri-cel was developed by China-based CARsgen.
The evidence. The randomized phase II CT041-ST-01 trial, led by Prof. Lin Shen at Peking University Cancer Hospital (Beijing Cancer Hospital), enrolled 156 patients with Claudin18.2-positive advanced stomach or GEJ cancer after at least two prior treatments. They received satri-cel or their doctor's choice of standard therapy (CancerNetwork, 2025; Lancet 2025):
Median progression-free survival: 3.25 vs. 1.77 months (HR 0.37)
Median overall survival: 7.92 vs. 5.49 months (HR 0.69)
Tumor response rate: 22% vs. 4%
Safety. Almost every patient (99%) had serious (grade 3 or higher) side effects, mostly very low blood counts from the chemotherapy given before infusion. Cytokine release syndrome, an inflammatory reaction, occurred in 95%. One treatment-related death occurred in each group (OncLive, June 2026).
Who it's approved for. Adults with Claudin18.2-positive, HER2-negative advanced gastric or GEJ adenocarcinoma whose disease progressed after at least two prior lines of therapy.
Be realistic. A gain of about 2.4 months in median survival matters, but satri-cel is not a cure for most patients. It involves cell collection, a manufacturing wait, chemotherapy before infusion and close monitoring afterward. Patients need to be well enough to tolerate the process, and for many that means considering it before their health declines further.
Within weeks of approval, international patients began traveling to China for satri-cel. One of the first documented was Josh Bronkhorst, a 59-year-old business executive from New Zealand with advanced gastroduodenal adenocarcinoma diagnosed in late 2025. Four months of chemotherapy and immunotherapy at home had not stopped his cancer (36Kr Europe, Sept 2026).
Testing in New Zealand showed his tumor was Claudin18.2-positive and HER2-negative, which made him eligible. He traveled to Shanghai in late June 2026, and his T cells were collected on July 6 at Jiahui International Cancer Center (Jiahui, July 2026). Before infusion, fluid buildup in his abdomen (malignant ascites) required draining up to 2,000 mL a day. By day 10 after infusion, the ascites had resolved and his drainage tube was removed. He has since returned home, with follow-up continuing (SmartShanghai, Aug 2026).
His own assessment was measured: "It's not a miracle drug, but this was by far the best option I could find" (ThePrint, Sept 2026, citing The Wall Street Journal).
One patient's early response does not predict another's. Long-term results for Josh have not been reported, and in the trial most patients' benefit was measured in months.
Immunotherapy: Sintilimab for First-Line Treatment
Sintilimab is a Chinese-developed PD-1 immunotherapy. In the ORIENT-16 phase III trial, led by Prof. Jianming Xu at the Fifth Medical Center of PLA General Hospital (Beijing), adding sintilimab to first-line chemotherapy improved median overall survival from 12.3 to 15.2 months in all patients, and from 12.9 to 19.2 months in patients with PD-L1 CPS of 5 or more (BioSpace / Innovent, Dec 2023; JAMA). It was approved in China for this use in June 2022.
What this means for you: first-line chemo-immunotherapy is now standard internationally too, using drugs such as nivolumab or pembrolizumab. Sintilimab is a comparable option, not a better one, since it was compared with chemotherapy alone.
HER2-Positive Stomach Cancer: A Chinese ADC in Development
Disitamab vedotin is a Chinese-developed HER2-targeted antibody-drug conjugate (ADC). In a phase II study led by Prof. Lin Shen, combining it with the PD-1 drug toripalimab and trastuzumab produced an 82.4% response rate versus 68.8% in the control arm among 51 first-line patients with HER2-overexpressing disease (CancerNetwork, June 2025). Progression-free survival differences were not yet statistically clear, and a phase III portion is ongoing.
Preventing Recurrence or Out of Options: What Is Being Studied
Two questions come up often: can anything lower the risk of recurrence after surgery, and what is left after satri-cel or other approved options? For stomach cancer, the answers are still in clinical trials.
CAR-T after surgery. CARsgen lists an investigator-initiated study of satri-cel as consolidation after adjuvant therapy in patients whose stomach or GEJ cancer has been surgically removed (CT041-CG4010, NCT06857786), aiming to clear any remaining cancer cells before they grow (CARsgen, June 2025). No results have been published. This is research, not an approved use.
Other cell therapies and vaccines. Personalized cancer vaccines, DC vaccines and TIL therapy are being studied in China for several solid tumors, but we have not verified published stomach cancer results from a named Chinese hospital. Hainan's Boao Lecheng medical zone can provide some therapies approved overseas but not yet in mainland China (Xinhua, Jan 2026); availability for stomach cancer must be confirmed case by case.
What this means for you: these are options to ask about, not to plan around. Trial eligibility is strict, and not every program accepts international patients.
Hospitals and Specialists Behind These Advances
The hospitals below are listed because they led one of the trials above, not as a general ranking.
Peking University Cancer Hospital (Beijing Cancer Hospital)
Fifth Medical Center of PLA General Hospital
Specialists Behind the Research
Doctor photos and profiles: Peking University Cancer Hospital and the Chinese medical-conference faculty directory. Research affiliation does not guarantee appointments or international-patient access.
China's Stomach Cancer Options at a Glance
On cost: CAR-T is expensive in every country, and we don't publish figures without a hospital quote. Ask what's included: cell collection, manufacturing, pre-treatment chemotherapy, hospital stay and follow-up.
What International Stomach Cancer Patients Should Know Before Traveling
Timing matters for CAR-T. Manufacturing cells takes time, and patients may need "bridging" treatment while they wait. Expect to stay in China for several weeks for infusion and monitoring.
You'll need Claudin18.2 and HER2 results. Chinese teams may ask to re-test your original tumor tissue, so bring pathology blocks or slides, not just reports.
Approval in China is not approval where you live. Satri-cel is approved only in China so far. Your home oncologist will need a clear plan for follow-up and managing late side effects.
Independent Guidance Before You Travel
ChinaCureLink (chinacurelink.com), a Medebound HEALTH company, is an independent medical facilitator and patient advocate helping international patients explore serious disease treatment in the US or in China. It was founded by physicians 10 years ago and has helped around 3,000 international patients.
For stomach cancer, the first question is usually whether your Claudin18.2, HER2 and PD-L1 results point to a Chinese option you can't get at home. ChinaCureLink represents the patient, not any hospital. Its team reviews your pathology and treatment history and matches your case with relevant Chinese hospitals and specialists. Applying and hospital and specialist matching are free. If you want a video second opinion with a Chinese gastrointestinal oncologist before deciding whether to travel, that is a paid consultation, and its fee is confirmed with you before booking.
Your Next Steps
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Frequently Asked Questions
Is CAR-T approved for stomach cancer?
Yes, in China. In June 2026, China approved satri-cel for Claudin18.2-positive, HER2-negative advanced gastric or GEJ adenocarcinoma after at least two prior treatments. It is not yet approved in the US or Europe.
How effective is satri-cel?
In its randomized trial, median overall survival was 7.92 months versus 5.49 months with standard options, and 22% of patients had tumor shrinkage. It extends survival for some patients but is not a cure for most.
Can foreigners receive satri-cel in China?
Possibly. It depends on your biomarkers, prior treatments, overall health and the treating hospital's policies. Eligibility must be confirmed with the hospital before travel.
What records should I prepare?
Pathology report and tissue blocks or slides, HER2, PD-L1 (CPS) and Claudin18.2 results if available, recent CT or PET scans, and a dated list of treatments and responses.
The Bottom Line
China has made real progress in stomach cancer, led by the first approved CAR-T for a solid tumor, along with Chinese immunotherapy and HER2-targeted drugs. But satri-cel helps a specific group — Claudin18.2-positive, HER2-negative, after two or more lines — and its benefits are modest.
The right first step is to get your Claudin18.2 status tested and have a specialist review whether any Chinese option fits your situation before you travel.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Sources and Further Reading
Medical Disclaimer
This article provides general information and does not replace individual medical advice. Eligibility, treatment access, risks, fees and follow-up require specialist assessment. Research findings do not guarantee outcomes. Confirm current access directly with the treating hospital before travel.
